Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: Results of the 2SMALL phase 1/2 study (NCT04253145).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Santiago Ponce Aix, Alejandro Navarro, Maria Eugenia Olmedo Garcia, Laura Mezquita, Margarita Majem, David Vicente, Reyes Bernabé, Alba Moratiel Pellitero, Manuel Cobo, Javier De Castro, Silverio Ros, Marta Lopez Brea, Rosario Garcia Campelo, Javier Baena, Helena Bote, Mercedes Herrera, Pedro Rocha, Jon Zugazagoitia, Enriqueta Felip, Luis G. Paz-Ares
Institutions: Hospital Universitario 12 De Octubre, Hospital Clínic de Barcelona, Hospital Universitario Ramón y Cajal, Hospital de Sant Pau, Hospital Universitario Virgen Macarena, Hospital Universitario Virgen del Rocío, Hospital Clínico Universitario Lozano Blesa, Hospital Regional Universitario de Málaga, Hospital Universitario La Paz, Hospital Universitario Virgen de la Arrixaca, Marqués de Valdecilla University Hospital, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Universidad Complutense de Madrid
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410820991